Fig. (1) Proportion of patients achieving (A) ACR20 response, (B) ACR50 response, (C) ACR70 response, (D) DAS28 LDA, (E) DAS28 remission, and (F) normal HAQ (≤0.5). Treatment modification was permitted at the start of the extension (i.e., after week 24); during the extension, 259/260 patients in the ETN + MTX group continued to receive etanercept and 105/126 patients in the DMARD + MTX group received etanercept. ACR, American College of Rheumatology; DAS28, Disease Activity Score in 28 joints; DMARD, disease-modifying antirheumatic drug; ETN, etanercept; HAQ, Health Assessment Questionnaire; LDA, low disease activity; LOCF, last observation carried forward; MTX, methotrexate. Analyses included patients who received at least one dose of study drug in the extension phase; LOCF.